Zobrazeno 1 - 10 of 59 pro vyhledávání: '"F. Rosenkaimer"'
2
Rationale for using TNFα and chemotherapy in regional therapy of melanoma
Autor: P Schmitz, Danielle Lienard, J. Vanderveken, B. B. R. Kroon, H. Schraffordt Koops, A. M. M. Eggermont, Joost M. Klaase, F. Rosenkaimer, Ferdy Lejeune, J. Gérain
Publikováno v: Journal of Cellular Biochemistry. 56:52-61
Recombinant tumor necrosis factor-alpha (rTNF alpha) has potent antitumor activity in experimental studies on human tumor xenografts. However, in humans, the administration of rTNF alpha is hampered by severe systemic side-effects. The maximum tolera
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba6352460dd2acaadbd776e92ee1b003
https://doi.org/10.1002/jcb.240560110
Zobrazit plný text záznamu
3
Recombinant tumor necrosis factor for superficial bladder tumors
Autor: Igea D'Agnano, Cora N. Sternberg, F. Calabresi, M. G. Arena, P. De Carli, M. Zeuli, A. Cancrini, F. Rosenkaimer, Gabriella Zupi, Vito Pansadoro
Publikováno v: Europe PubMed Central
Twenty patients with histologically documented superficial bladder cancer (Ta, T1, Tis) were treated with intravesical administration of TNF 400-1800 micrograms. Of 18 patients with a marker lesion, 2 obtained a complete response for 8+ and 18 months
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20a0dae3dd9faa96cc32b21050ee2040
https://doi.org/10.1093/oxfordjournals.annonc.a058331
Zobrazit plný text záznamu
4
[Efficacy of the tumor necrosis factor-alpha (rTNF-alpha) associated with interferon-gamma and chemotherapy in extracorporeal circulation in the limb in inoperable malignant melanoma, soft tissue sarcoma and epidermoid carcinoma. A 4-year experience]
Autor: F, Lejeune, D, Liénard, A, Eggermont, H, Schraffordt Koops, F, Rosenkaimer, J, Gérain, J, Klaase, B, Kroon, P, Schmitz
Publikováno v: Bulletin du cancer. 82(7)
The authors review their experience of 4 years with isolated limb perfusion for the application of high dose TNF-alpha associated to IFN-gamma and melphalan for the treatment of regionally advanced tumours such as malignant melanoma, soft tissue sarc
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::fdfe9ebef5860326ed2a6099a24fe1b2
https://pubmed.ncbi.nlm.nih.gov/7549119
Zobrazit plný text záznamu
5
Administration of high-dose tumor necrosis factor alpha by isolation perfusion of the limbs. Rationale and results
Autor: F, Lejeune, D, Liénard, A, Eggermont, H, Schraffordt Koops, F, Rosenkaimer, J, Gérain, J, Klaase, B, Kroon, J, Vanderveken, P, Schmitz
Publikováno v: The Journal of infusional chemotherapy. 5(2)
Recombinant tumor necrosis factor alpha (rTNF alpha) has potent antitumor activity in experimental studies on human tumor xenografts. However, in humans, the administration of rTNF alpha is hampered by severe systemic side effects. The maximum tolera
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::95a2cd1902cf5fb4bf950e0960f27173
https://pubmed.ncbi.nlm.nih.gov/8521239
Zobrazit plný text záznamu
6
Clinical experience with high-dose tumor necrosis factor alpha in regional therapy of advanced melanoma
Autor: F, Lejeune, D, Liénard, A, Eggermont, H, Schraffordt Koops, B, Kroon, J, Gérain, F, Rosenkaimer, P, Schmitz
Publikováno v: Circulatory shock. 43(4)
Isolated perfusion of the limbs (ILP) allows the delivery of high dose rTNF alpha in a closed system with acceptable side-effects. A protocol with a triple-drug regimen was based on the reported synergism of rTNF alpha with chemotherapy, with interfe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7257d8061092c59026019c64744fd0c0
https://pubmed.ncbi.nlm.nih.gov/7895325
Zobrazit plný text záznamu
8
Low incidence of antibody formation due to long-term interferon-alpha 2c treatment of cancer patients
Autor: G. Bidlingmaier, B. Göd, G. G. Steinmann, F. Rosenkaimer, H. Lamche, J. Lindner, G. Adolf, C. Schmähling, F. J. Schneider, E. Patzelt, B. Frühbeis
Publikováno v: The Clinical investigator. 70(2)
In order to study the long-term immunogenicity of interferon-alpha 2c (Berofor) in cancer patients, serum was collected starting in 1983 from study patients with various proliferative diseases who received interferon-alpha 2c at different doses, acco
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d3db04085d7182307cd81f357fed6d2
https://pubmed.ncbi.nlm.nih.gov/1600338
Zobrazit plný text záznamu
9
A randomized trial comparing a pentavalent antimonial drug and recombinant interferon-gamma in the local treatment of cutaneous leishmaniasis
Autor: M. Roepke, Ulrich Bienzle, A. Mouakeh, A.K. Chehade, Gundel Harms, F. Rosenkaimer, M. Douba
Publikováno v: Transactions of the Royal Society of Tropical Medicine and Hygiene. 85(2)
In a randomized prospective trial N-methyl-glucamine antimoniate (Glucantime) and human recombinant interferon-gamma were infiltrated around lesions of cutaneous leishmaniasis caused by Leishmania tropica in Syria. A previous trial had shown that int
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6850febbc9b21414eab08371da25b56
https://pubmed.ncbi.nlm.nih.gov/1909469
Zobrazit plný text záznamu
10
Topical alpha interferon in the treatment of oral ulcers in Behçet's syndrome: a preliminary report
Autor: V, Hamuryudan, S, Yurdakul, S, Serdaroglu, Y, Tüzün, F, Rosenkaimer, H, Yazici
Publikováno v: Clinical and experimental rheumatology. 8(1)
The effect of topical recombinant interferon alfa 2c hydrogel (IFN alpha 2C) in the aphthous lesions of the mouth in Behcet's syndrome was assessed in twenty patients in a twelve-week open trial. IFN alpha 2C applied to the mouth for four weeks signi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f6b0f4fa4932f7140df966cd3228c740
https://pubmed.ncbi.nlm.nih.gov/2189624
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje